In this study it was reported that ASO CD39 treatment significantly increased the ratio of CD8 to Tregs, and that combination of ASO CD39 with anti PD-1 mAb resulted in reduced tumor volume [61]. This evidence concerns the gene PDCD1 and neoplasm.